Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10-Reference-Cited by-全球学者库

登录注册会员服务联系我们

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10

Published:2023-12 Issue: Volume:198 Page:106988
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Huang Mu-Yang,Chen Yu-Chi,Lyu Wen-Yu,He Xin-Yu,Ye Zi-Han,Huang Can-Yu,He Xin-Ling,Chen Xiuping,Chen Xiaobing,Zhang Baoxian,Kai Guoyin,Zhang Xiaolei,Li Ting,Huang Mingqing,Lu Jin-Jian

Publisher

Elsevier BV

Subject

Pharmacology

Reference61 articles.

1. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future;Chen;J. Clin. Invest,2015

2. Regulation and function of the PD-L1 checkpoint;Sun;Immunity,2018

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell;Reck;Lung Cancer, N. Engl. J. Med,2016

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N. Engl. J. Med.,2018

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP